PMID- 19506330
OWN - NLM
STAT- MEDLINE
DCOM- 20091106
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 56
IP  - 5
DP  - 2009
TI  - Pioglitazone improves endothelial function with increased adiponectin and 
      high-density lipoprotein cholesterol levels in type 2 diabetes.
PG  - 691-8
AB  - Endothelial dysfunction is considered to be an early event in the development of 
      atherosclerosis. The present study was undertaken to evaluate endothelial 
      function and biochemical markers in type 2 diabetes mellitus (T2DM) patients 
      before and after treatment with or without pioglitazone (PIO). Forty-one T2DM 
      patients without macroangiopathy were randomized to treatment with (n=20) or 
      without (control, n=21) PIO for 12 weeks. Endothelial function was assessed by 
      flow-mediated vasodilation (FMD) using a high-resolution ultrasound method before 
      and after treatment. After treatment, HbA1c levels equally decreased in both 
      groups, but PIO-treated group had significantly increased high-density 
      lipoprotein cholesterol (HDL-C) levels, and decreased triglyceride, fasting 
      insulin levels and HOMA-R. After treatment, increases in %FMD, plasma HDL-C and 
      adiponectin (APN) levels were significantly greater in PIO-treated group than 
      those in control group. Changes of %FMD showed significant positive correlations 
      with those of plasma APN and HDL-C levels. In conclusion, the present study 
      showed that treatment of T2DM improved endothelial function with greater 
      increases in %FMD, APN and HDL-C levels in PIO-treated group than those in 
      control group, suggesting the beneficial effect of PIO on endothelial function in 
      T2DM.
FAU - Tsuchiya, Kyoichiro
AU  - Tsuchiya K
AD  - Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental 
      University Graduate School, Tokyo, Japan. ktsuchiya.cme@tmd.ac.jp
FAU - Akaza, Itaru
AU  - Akaza I
FAU - Yoshimoto, Takanobu
AU  - Yoshimoto T
FAU - Hirata, Yukio
AU  - Hirata Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090609
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Adiponectin)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adiponectin/*blood
MH  - Aged
MH  - Cholesterol, HDL/*blood
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Endothelium, Vascular/*drug effects/physiology/physiopathology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Thiazolidinediones/*therapeutic use
MH  - Vasodilation/drug effects/physiology
EDAT- 2009/06/10 09:00
MHDA- 2009/11/07 06:00
CRDT- 2009/06/10 09:00
PHST- 2009/06/10 09:00 [entrez]
PHST- 2009/06/10 09:00 [pubmed]
PHST- 2009/11/07 06:00 [medline]
AID - JST.JSTAGE/endocrj/K08E-308 [pii]
AID - 10.1507/endocrj.k08e-308 [doi]
PST - ppublish
SO  - Endocr J. 2009;56(5):691-8. doi: 10.1507/endocrj.k08e-308. Epub 2009 Jun 9.